INTRODUCTION
============

Recent explosive advances in multi-omics have provided us with powerful tools to investigate the pathophysiological complexity of disease processes. In Mendelian diseases, the application of a single-omic approach, such as whole exome sequencing (WES), has dramatically reduced the time and effort required to identify causative mutations \[[@B1]\]. Thus, the next step, in which multi-omics are effectively applied to Mendelian diseases, might reveal biochemical and biophysical abnormalities that present therapeutic targets for personalized medicine.

Compared with the biochemical information available about the central nervous system (CNS), that available for the peripheral nervous system (PNS) is quite limited, thereby therapeutic approaches to the PNS diseases more difficult. Characterization of the core pathology, in conjunction with the identifications of genetic causes, is a prerequisite to the development of personalized medicine for genetically and clinically heterogeneous disorder, such as hereditary motor and sensory neuropathy (HMSN) \[[@B2]\].

HMSN is frequently classified as type 1, demyelinating form (HMSN1), or type 2, axonal form (HMSN2). HMSN1 exhibits markedly reduced nerve conduction velocities (NCV), whereas HMSN2 shows slightly reduced or even normal NCVs. HMSN2 is occasionally difficult to distinguish phenotypically from distal hereditary motor neuropathy (dHMN) which is closely resembles HMSN but without sensory abnormality, because sensory signs are often lacking in HMSN2 patients \[[@B3]\].

Recent monumental attempts to decipher the transcriptome in the human brain have undoubtedly contributed to our anatomical understanding of the transcriptional network and disease-related changes in inaccessible tissues \[[@B4], [@B5]\]. Subsequent proteomic or metabolomic analyses will provide further crucial information in the near future. Therefore, documentation of the transcriptome in the human distal sural nerve might provide primary knowledge as a basis for understanding the pathophysiology of PNS diseases. Here, we performed the transcriptome analysis using distal sural nerve of HMSN patients.

PATIENTS AND METHODS
====================

Patients
--------

This study included a total of 14 individuals of Korean origin with HMSN or normal phenotype. Written informed consent was obtained from all the participants and from the parents of participants younger than 18 years, according to the protocol approved by the Institutional Review Board of Ewha Womans University, Mokdong Hospital (ECT 11-58-37).

Clinical assessments
--------------------

The patients were examined for motor and sensory impairment, deep tendon reflexes, and muscle atrophy by two independent neurologists. The muscle strengths of the flexor and extensor were assessed manually using the Medical Research Council scale. Physical disabilities were expressed on two different scales: the Functional Disability Scale (FDS) \[[@B6]\] and Charcot-Marie-Tooth disease neuropathy score (CMTNS) \[[@B7]\] (see [Table 1](#T1){ref-type="table"}). Disease severity was determined using a nine-point FDS, which was based on the following criteria: 0, normal; 1, normal but with cramps and fatigability; 2, an inability to run; 3, walking difficulty but still possible unaided; 4, walking with a cane; 5, walking with crutches; 6, walking with a walker; 7, wheelchair bound; and 8, bedridden. In addition, we determined the CMTNS, and the patient was divided into mild (CMTNS≤10), moderate (CMTNS, 11-20), and severe (CMTNS≥21) categories.

Sural nerve biopsy
------------------

Sural nerves from 14 individuals were obtained by incision under sterile conditions and local anesthesia \[[@B8]\]. After obtaining about 10 mm length of nerve, sharp dissection followed to obtain pure sural nerve.

Transcriptome analysis
----------------------

RNA-Seq data were generated from all 14 samples. The cDNA library was prepared using the TruSeq RNA Sample Preparation Kit (Illumina, San Diego, CA). The sequencing protocol consisted of total RNA extraction from a biopsy of the distal sural nerve and polyA RNA extraction, RNA fragmentation, random-hexamer-primed reverse transcription, and 100 nt paired-end sequencing with HiSeq 2000 (Illumina). To estimate the expression levels and to identify alternatively spliced transcripts, the RNA-Seq reads were mapped to the human genome using TopHat (version 1.3.3, <http://tophat.cbcb.umd.edu/index.html>). Then all variants were annotated by the ANNOVAR (version 2011Feb20) program. To determine whether the variants were previously reported, dbSNP135 (<http://www.ncbi.nlm.nih.gov>) was used. The transcript levels were calculated and the relative transcript abundances were measured in fragments per kilobase of exon per million fragments mapped (FPKM) using Cufflinks (<http://cufflinks.cbcb.umd.edu/index.html>). The deFuse program (version 0.4.3, <http://sourceforge.net/apps/mediawiki/defuse>) was used to identify gene fusions from the RNA-Seq data because this program considered all alignments and all possible locations for fusion boundaries \[[@B9]\].

Whole-exome sequencing
----------------------

Total DNA was purified from peripheral blood with a QIAamp Blood DNA Purification Kit (Qiagen, Hilden, Germany). The whole exome was captured using SeqCap EZ V3.0 (Roche-NimbleGen, Madison, WI), and sequencing was performed using the HiSeq 2000 Genome Analyzer (Illumina). The UCSC assembly hg19 (NCBI build 37.1) was used as the reference sequence. Variant calling was achieved for those with ≥20 SNP quality. The variants were annotated with the ANNOVAR program.

RESULTS AND DISCUSSION
======================

To investigate the transcriptional profile in the human distal sural nerve which is the most common tissue for observation of pathophysiology of PNS, we enrolled 14 Korean individuals. RNA-Seq and subsequent analyses were used to generate mRNA expression profiles in which fragments per kilobase of transcript per million fragments mapped (FPKM) was used to quantify each transcript. Using a threshold of FPKM\>1, which corresponds to approximately one transcript per cell \[[@B10]\], we found that over 12,000 transcripts are expressed in the human distal sural nerve ([Table 1](#T1){ref-type="table"} and [Supplementary Material](#S1){ref-type="supplementary-material"}) is almost equivalent to the number expressed in human lymphoblastoid cells (11,000 active transcripts), which was calculated by a similar analytical parameter \[[@B11]\].

RNA-Seq also identified over 4,000 unreported transcripts (FPKM \> 1) per sample. As genome tiling arrays revealed over 10,000 novel transcripts in the human liver \[[@B12]\], the transcriptional events in the human distal sural nerve are also dynamic. We also found that around 10 transcripts per sample were fused in both the controls and patients ([Table 1](#T1){ref-type="table"}). However, we have no clue to the function or biochemical significance of these unreported and fused transcripts in this tissue.

Our transcriptome analysis also revealed over 5,000 functionally significant variants (nonsynonymous splicing site, stop gain/loss, and coding indels) in each sample. Because these variants might primarily derive from changes in the genomic DNA, we analyzed the genomic variants in nine samples from peripheral blood DNA using WES. WES revealed that over 9,000 functionally significant variants are present per sample. Therefore, the variants of transcriptome are fewer than those of genome. Next, we calculated transcriptional base modifications (TBMs) by comparing the two data sets. TBM analysis revealed that there are over 1,500 functionally significant variants. Among them 77% (over 1,200 variants) were unreported to dbSNP135. Although these might include many false positives, arising from methodological or analytical limitations and the discordance of data sources, these data imply that dramatic alterations occur when genetic information is actively transitioned in specific tissues. The significance of TBM is still unclear, until its correlation with disease onset, progression, susceptibility, or penetrance is reported.

Based on this expression profile, we analyzed the changes in the expression patterns of HMSN-causative genes and tried to identify the genes that were differentially expressed in the patients and the controls. Several changes in putative mechanistic/metabolic pathways were identified in the HMSN patient groups (data not shown), but the heterogeneity and size of the samples limited the statistical validity of the results. Nonetheless, future well-designed *in vitro* experimental approaches might convert parts of these data into valid information, which will allow us to understand the pathophysiology of the disease and may suggest therapeutic strategies.

In summary, we first generated a transcriptional profile of the human distal sural nerve, providing basic information about the gene expression in this tissue based on pathophysiological studies of HMSN. Our data also suggest that considerable numbers of events occur beyond the information encoded in the DNA, which has been the main source of biomedical information in the pre-omics era. The contribution of multi-omics might accelerate the biomedical approaches in the PNS by presenting systematic information. Subsequent studies that characterize these novel transcripts and TBMs and validate the HMSN-related changes in the expression profile will provide crucial information about the pathological mechanism of HMSN and provide therapeutic options for each genetic causative.
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SUPPLEMENTARY MATERIAL
======================

###### Supplementary Material

Supplementary questionnaire can be found via <http://en-journal.org/src/sm/en-23-169-s001.xlsx>

Questionnaires for Peyronie disease.

###### 

Patients enrolled in this study and transcriptome analysis results

![](en-23-169-i001)

^a^Age at sural nerve biopsy; ^b^Functional disability scale \[[@B6]\]; ^c^Charcot-Marie-Tooth disease neuropathy score \[[@B7]\]; ^d^Expressed transcripts were determined as FPKM\>1. Original data are available in [Supplementary Material](#S1){ref-type="supplementary-material"}; ^e^Novel transcripts determined with the Cufflinks program and FPKM\>1; ^f^Gene fusion was analyzed with the deFuse software; ^g^Nonsynonymous splicing site, stop gain/loss, and coding indels; ^h^Variants unreported in dbSNP135; ^i^Transcriptional base modifications; ^j^Number of transcriptome variants that were not identified in the whole-exome analysis; ^k^Nonsynonymous splicing site, stop gain/loss, and coding indels that are not reported in dbSNP135; ^l^causative gene was not defined.
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